摘要
目的探讨在阿尔茨海默病(AD)和帕金森痴呆(PDD)患者脑脊液(CSF)中tau蛋白和β淀粉样蛋白(Aβ1-42)的水平及临床意义。方法同时将符合美国国立神经病、语言障碍和脑卒中研究所-老年性痴呆及相关性疾病协会的“很可能AD”标准的22例AD组患者与20例PDD组患者和21例性别、年龄相匹配的无中枢神经系统疾患、无痴呆表现的心理疾病患者作为对照组(NC组)进行研究。结果3组CSF中tau蛋白平均浓度比较,AD组明显高于NC组(P<0.05);AD组与PDD组差异无显著性意义(P>0.05)。3组CSF中A1β-42平均浓度比较,AD组明显低于NC组(P<0.05),PDD组与NC组差异无显著性意义(P>0.05)。结论AD患者CSF中tau蛋白和Aβ1-42浓度变化是其重要的实验室表现,可以作为AD的辅助诊断指标和与PDD早期鉴别诊断的可能生物学指标。
Objective To investigate the levels and clinical significance of β-amyloid peptide1-42 （Aβ1-42） in cerebrospinal fluid （CSF） of patients with Alzheimer＇ s disease （AD） and Parkinson＇ s dementia （PDD）. Methods The subjects were 22 patients with AD, 20 patients with PDD and 21 controls（NC）. The CSF levels of tau and Aβ1-42 of each subject were measured by enzyme linked immunosorbent assay （ELISA）. Results The mean CSF level （ng/L） of tau of AD group was significantly higher than that of NC group, but there was no significant difference between AD and PDD groups. The mean CSF level （ng/L） of Aβ1-42 of AD group was significantly lower than that of NC group （ P 〈 0.05 ）. However, no significant difference was observed between PDD group and NC group（ P 〉 0.05）. Conclusions The CSF levels of tau and Aβ1-42 of patients with AD could be the indexes for diagnosing AD early and differential diagnosis from PDD.
出处
《中华老年心脑血管病杂志》
CAS
北大核心
2007年第2期113-115,共3页
Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
基金
河南省教育厅自然科学基金项目(2004922065)
作者简介
张萍，女，1972年9月生，河南省新乡市人，主治医师，硕士，从事神经内科专业。
